S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:VTGN

VistaGen Therapeutics - VTGN Stock Forecast, Price & News

$0.16
-0.02 (-11.27%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.15
$0.17
50-Day Range
$0.14
$1.15
52-Week Range
$0.14
$3.26
Volume
20.45 million shs
Average Volume
4.71 million shs
Market Capitalization
$32.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

VistaGen Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
5,617.9% Upside
$9.00 Price Target
Short Interest
Healthy
5.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of VistaGen Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$53,400 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.28) to ($0.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

452nd out of 1,117 stocks

Pharmaceutical Preparations Industry

220th out of 550 stocks

VTGN stock logo

About VistaGen Therapeutics (NASDAQ:VTGN) Stock

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

VistaGen Therapeutics Stock Performance

Shares of VistaGen Therapeutics stock opened at $0.18 on Friday. The business's 50 day simple moving average is $0.71 and its 200 day simple moving average is $1.10. VistaGen Therapeutics has a 52-week low of $0.14 and a 52-week high of $3.26. The firm has a market cap of $36.16 million, a PE ratio of -0.73 and a beta of 0.53.

VistaGen Therapeutics (NASDAQ:VTGN - Get Rating) last announced its earnings results on Thursday, June 23rd. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). VistaGen Therapeutics had a negative net margin of 4,306.76% and a negative return on equity of 61.44%. During the same period last year, the business posted ($0.20) earnings per share. As a group, equities research analysts predict that VistaGen Therapeutics will post -0.28 EPS for the current year.

Analyst Upgrades and Downgrades

VTGN has been the subject of several recent analyst reports. William Blair downgraded VistaGen Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday, July 22nd. Jefferies Financial Group downgraded VistaGen Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, July 22nd. Maxim Group downgraded VistaGen Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, July 26th. Finally, Robert W. Baird downgraded VistaGen Therapeutics from an "outperform" rating to a "neutral" rating in a report on Friday, July 22nd.

Insider Activity at VistaGen Therapeutics

In other VistaGen Therapeutics news, major shareholder Venrock Healthcare Capital Par sold 60,000 shares of the business's stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $0.89, for a total transaction of $53,400.00. Following the transaction, the insider now owns 20,637,286 shares of the company's stock, valued at approximately $18,367,184.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.67% of the stock is owned by insiders.

Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTGN Stock News Headlines

VistaGen Therapeutics earnings preview: what to expect
VistaGen Therapeutics Inc - Stock Chart
VistaGen stock down 7% on disappointing FY result
VistaGen Therapeutics earnings: here's what Wall Street expects
See More Headlines
Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTGN Company Calendar

Last Earnings
6/23/2022
Today
8/12/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTGN
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+5,617.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-47,760,000.00
Net Margins
-4,306.76%
Pretax Margin
-4,306.49%

Debt

Sales & Book Value

Annual Sales
$1.11 million
Book Value
$0.31 per share

Miscellaneous

Free Float
199,057,000
Market Cap
$32.53 million
Optionable
Not Optionable
Beta
0.53

Key Executives

  • Mr. Shawn K. Singh J.D. (Age 59)
    CEO & Director
    Comp: $912.5k
  • Mr. Jerrold D. Dotson CPA (Age 69)
    CPA, CFO, VP & Sec.
    Comp: $577.5k
  • Mr. Reid G. Adler Esq. (Age 68)
    J.D., Chief Legal Officer
  • Dr. Mark A. Smith M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $658.75k
  • Ms. Ann Michelle Cunningham M.B.A. (Age 54)
    Chief Commercial Officer & Director
    Comp: $576.44k
  • Mr. Mark Flather
    VP of Investor Relations
  • Mr. Mark Adrian McPartland (Age 56)
    VP of Corp. Devel.
  • Ms. Trisha Fitzmaurice
    VP of HR
  • Dr. Allen Easley Cato III
    M.D., Ph.D., Sr. VP of Devel. Operations
  • Dr. Mark J. Ginski (Age 50)
    Sr. VP and Head of Chemistry, Manufacturing & Controls













VTGN Stock - Frequently Asked Questions

Should I buy or sell VistaGen Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" VTGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VTGN, but not buy additional shares or sell existing shares.
View VTGN analyst ratings
or view top-rated stocks.

What is VistaGen Therapeutics' stock price forecast for 2022?

4 Wall Street analysts have issued twelve-month price targets for VistaGen Therapeutics' shares. Their VTGN share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 5,672.9% from the stock's current price.
View analysts price targets for VTGN
or view top-rated stocks among Wall Street analysts.

How have VTGN shares performed in 2022?

VistaGen Therapeutics' stock was trading at $1.95 at the start of the year. Since then, VTGN shares have decreased by 92.0% and is now trading at $0.1559.
View the best growth stocks for 2022 here
.

Are investors shorting VistaGen Therapeutics?

VistaGen Therapeutics saw a decline in short interest in July. As of July 31st, there was short interest totaling 9,040,000 shares, a decline of 46.1% from the July 15th total of 16,770,000 shares. Based on an average daily volume of 8,330,000 shares, the days-to-cover ratio is presently 1.1 days. Approximately 5.8% of the shares of the company are sold short.
View VistaGen Therapeutics' Short Interest
.

When is VistaGen Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our VTGN earnings forecast
.

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) released its earnings results on Thursday, June, 23rd. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.03. VistaGen Therapeutics had a negative trailing twelve-month return on equity of 61.44% and a negative net margin of 4,306.76%. During the same period last year, the firm earned ($0.20) EPS.

What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

What is VistaGen Therapeutics' stock symbol?

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Who are VistaGen Therapeutics' major shareholders?

VistaGen Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (4.57%), MAI Capital Management (1.29%), Epiq Partners LLC (0.63%), Oak Family Advisors LLC (0.19%), Assenagon Asset Management S.A. (0.17%) and Dorsey & Whitney Trust CO LLC (0.07%). Insiders that own company stock include H Ralph Snodgrass, Jerrold Duane Dotson and Venrock Healthcare Capital Par.
View institutional ownership trends
.

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VistaGen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $0.16.

How much money does VistaGen Therapeutics make?

VistaGen Therapeutics (NASDAQ:VTGN) has a market capitalization of $32.22 million and generates $1.11 million in revenue each year. The company earns $-47,760,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How can I contact VistaGen Therapeutics?

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.vistagen.com. The company can be reached via phone at (650) 577-3600, via email at ir@vistagen.com, or via fax at 888-482-2602.

This page (NASDAQ:VTGN) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.